Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$48.54 USD

48.54
4,701,423

+0.73 (1.53%)

Updated Aug 15, 2025 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Sweta Killa headshot

S&P Reclaims 3,000: Buy 6 Stocks With More Than 25% Growth

In the latest market rally driven by hopes surrounding potential coronavirus vaccines and reopening of the economy, the S&P 500 reclaimed its 3,000 level and is poised to rise further.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson

The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson

Zacks Equity Research

Sanofi to Sell Stake in Regeneron, Existing Deal Unchanged

Sanofi (SNY) intends to sell majority of its shareholding in its collaboration partner, Regeneron. However, there will be no change in the ongoing collaboration terms.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales

FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.

Zacks Equity Research

Simple Secrets Anyone Can Use to Reach Early Retirement - May 21, 2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

Zacks Equity Research

Incyte, MorphoSys Application for Lymphoma Drug Validated

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, Fidelity National Information Services, Alibaba and Bristol-Myers Squibb

The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, Fidelity National Information Services, Alibaba and Bristol-Myers Squibb

Zacks Equity Research

These 4 High Earnings Yield Stocks are Hot Investment Picks

Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.

Zacks Equity Research

Signs That Your Trading Will Ruin Your Retirement - May 19, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Zacks Equity Research

Roche's Tecentriq Gets FDA Approval for Metastatic NSCLC

Roche (RHHBY) gets FDA approval for the label expansion of Tecentriq into metastatic NSCLC as a first-line monotherapy.

Zacks Equity Research

Zacks.com featured highlights include: Taiwan Semiconductor Manufacturing Company, Dollar General, Kroger, Bristol-Myers Squibb and NIC

Zacks.com featured highlights include: Taiwan Semiconductor Manufacturing Company, Dollar General, Kroger, Bristol-Myers Squibb and NIC

Sheraz Mian headshot

Top Stock Reports for Facebook, JNJ, FIS & Others

Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Johnson & Johnson (JNJ) and Fidelity National Information Services, Inc. (FIS).

Zacks Equity Research

Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

Zacks Equity Research

BMY or MRK: Which Is the Better Value Stock Right Now?

BMY vs. MRK: Which Stock Is the Better Value Option?

Zacks Equity Research

Bristol Myers' Opdivo+Yervoy Gets FDA Nod in First-Line NSCLC

Bristol-Myers (BMY) Opdivo in combination with Yervoy gets FDA nod for the first-line treatment of NSCLC patients.

Sweta Killa headshot

5 Great Dividend Growth Stocks for Income and Safety

In a near-zero interest environment and amid a series of drastic dividend cuts, investors are seeking consistent and safe income thereby driving the appeal for dividend investing.

Zacks Equity Research

Merck's (MRK) Keytruda Successful in Several Cancer Studies

Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.

Zacks Equity Research

Seattle Genetics' Adcetris Label Expands in EU for Lymphoma

Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY

FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.

Zacks Equity Research

Roche Posts Positive Phase II Results on Immunotherapy Combo

Roche's (RHHBY) mid-stage study on immunotherapy, tiragolumab, combined with PD-L1 checkpoint inhibitor, Tecentriq, meets co-primary endpoints.

Zacks Equity Research

The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY

The Zacks Analyst Blog Highlights: LLY, AZN, PFE, SNY and BMY

Zacks Equity Research

Bristol-Myers Gets Refusal to File Letter for CAR-T Therapy BLA

Bristol-Myers' (BMY) BLA seeking approval for CAR-T therapy candidate, idecabtagene vicleucel, for treating relapsed and refractory multiple myeloma gets FDA's refusal. The company plans to re-submit the BLA by July.

Nalak Das headshot

Rebalance Your Portfolio to Counter Dilemma Over Recovery

At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.

Zacks Equity Research

Powerful Proof Anyone Can Invest for an Early Retirement - May 13, 2020

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.

Kinjel Shah headshot

Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks

Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.